Valuation dashboard for Moleculin Biotech, Inc. (MBRX) with P/E N/A, P/B 0.37, EV/EBITDA 0.10 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.74, MBRX has negative trailing earnings (P/E not meaningful) and an ROE of -8.17%. Market capitalisation stands at $4M.
Balance sheet quality for MBRX: current ratio of 1.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.37 |
| EV / EBITDA | 0.10 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.54 |
| vs Current Price | +512.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | $4M | 0.37 | -8.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.74 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -816.56% |
| Return on Invested Capital | -242.25% |
| Return on Assets | -143.82% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · AIMD · APLM · ATHA · BLRX · CTXR · ICU
Explore sector: Healthcare · Biotechnology
More sections of MBRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks